Harrow Health, Inc. (HROW) Q2 FY26 Earnings Call

The investment case depends on converting strong product demand and commercial investments into a substantial second-half revenue and EBITDA ramp.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-11
Length69 minutes
EPS$-0.34
EPS consensus$-0.23
Revenue$44.2M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All HROW earnings ยท Back to HROW overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.